Home
The Infectious Diseases Clinical Research Consortium (IDCRC) and Vaccine and Treatment Evaluation Units (VTEUs) work in tandem with the National Institute of Allergy and Infectious Diseases (NIAID) as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.
About
The IDCRC works through a flexible, sustaining structure to advance new countermeasures and approaches to product development, implement efficient clinical study/trial designs, and support exceptional career development and mentoring of future leaders in infectious diseases clinical research. The consortium's collective experience and access to diverse populations give it the ability to evaluate new vaccines and therapies for infectious diseases.
IDCRC study finds rapid decline in vaccine-boosted neutralizing antibodies against Omicron variant BA.5
Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substantially within three months, according to new clinical trial data.
Read More
COVID-19 Prevention Network
The CoVPN was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network; the HIV Prevention Trials Network; the Infectious Diseases Clinical Research Consortium; and the AIDS Clinical Trials Group.
More about the CoVPN
News from VTEU Trials
IDCRC Leadership Group
IDCRC Vaccine & Treatment Evaluation Units (VTEUs)
IDCRC Concept Quick Stats
ICP Status
- Approved: 40
- Administratively Not Supported: 23
- Revise & Resubmit: 5
- Withdrawn: 12
- Liaisons: 0
- EWGs: 2
- Not Approved: 37
- EMT: 0
- Other: 8
EWG Assignment
- COVID: 85
- Respiratory: 14
- STI: 8
- Malaria/Topical Diseases: 7
- Enteric Infections: 4
- Emerging Infections: 8
- Monkeypox: 2
ECP
- Protocol Development: 8
- IDCRC Concept Study Underway: 4
- Moved forward through other processes: 4
- Pending: 6
- Not approved: 3
- In Process: 11
- Hold: 5
- Withdrawn: 3
- Note: Protocols Transitioned to IDCRC for Protocol Implementation: 5
- Other studies in process not from IDCRC concepts (MOMI-VAX, Moderna Pediatric, Moderna Variant, Moderna Boost): 5
- Note: one concept was referred to both Emerging Infections & STI EWGs
IDCRC Citation Statement
Please include the following citation in any publications resulting from direct or indirect IDCRC support:
"Supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health, under award number UM1AI148684. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health."